Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
ArriVent Logo
ArriVent Growth Score
74
CB Rank
3433
Heat Score
47
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
Founded
obfuscation
PublicPost-IPO Equity Pennsylvania Furnace, Pennsylvania, United States101-250 arrivent.com/
Biotechnology
Life Science
Oncology
Pharmaceutical
Overview

ArriVent
Total Funding
obfuscation
Growth Score
74
Heat Score
47

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score74
6 pts
in past quarter
Heat Score 47
5 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
+2 more milestones
See more interactive data and historical milestones on desktop for the best experience

About ArriVent

CB Rank
3433
ArriVent develops pharmaceutical products to cure presently untreatable cancer.
Founded
obfuscation
PublicPost-IPO Equity Pennsylvania Furnace, Pennsylvania, United States101-250 arrivent.com/
Biotechnology
Life Science
Oncology
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Post-IPO Debt
OBF
in
obfuscation

Key People

Details

Legal Name ArriVent BioPharma, Inc.
Also Known As ArriVent, ArriVent BioPharma
Operating Status Active
Stock Symbol  NASDAQ:AVBP
Company Type For Profit
Founders  Bing Yao, Robin LaChapelle, Stuart Lutzker
About the Company
ArriVent is a biopharmaceutical company developing pharmaceutical products to cure presently untreatable cancer.
Contact Email info@arrivent.com
Predictions & Insights

Growth Insight

See this Growth Insight
ArriVent is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Products & Services

Firmonertinib
An oral, brain-penetrant EGFR inhibitor targeting classical and uncommon EGFR mutations in non-small cell lung cancer (NSCLC).
ARR-217
An antibody-drug conjugate (ADC) targeting gastrointestinal cancers, licensed for global development outside Greater China.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - ArriVent Logo
Post-IPO Equity - ArriVent
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - ArriVent Logo
Post-IPO Debt - ArriVent
—
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - ArriVent Logo
Post-IPO Debt - ArriVent
—
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - ArriVent Logo
Post-IPO Debt - ArriVent
—
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - ArriVent Logo
Post-IPO Debt - ArriVent
—
Silicon Valley Bank Logo
Silicon Valley Bank
Yes
Post-IPO Debt - ArriVent Logo
Post-IPO Debt - ArriVent
—
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 8 Board Members and Advisors 2 Contacts 30

Employee Profiles

Board Members and Advisors

News

News and Press

News•May 12, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 11, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 8, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

3,617
79.5%
 in past month

IT Spend

$2MThis year, ArriVent is projected to spend $2M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Business Insider Logo
Business Insider
94
Mutual Action Plan Logo
Mutual Action Plan
89
Sonos Logo
Sonos
83

Active Website Tech Count

25ArriVent is actively using 25 technologies for its website, according to BuiltWith. These include IPhone / Mobile Compatible, DNSSEC, and  reCAPTCHA.
Sub-Organizations
Frequently Asked Questions

Where is ArriVent's headquarters? ArriVent is located in Pennsylvania Furnace, Pennsylvania, United States.Who invested in ArriVent? ArriVent has 20 investors including Silicon Valley Bank and  Infinitum.When was the last funding round for ArriVent? ArriVent closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are ArriVent's competitors? Alternatives and possible competitors to ArriVent may include Calidi Biotherapeutics, Canton Strategic Holdings, and  Candel Therapeutics.How much funding has ArriVent raised to date? ArriVent has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(5eb04bf 1)
|